You stay full longer, eat less, and avoid sugar spikes
As this promising treatment for weight loss works toward FDA approval, it is not yet available via standard prescription
Anti-inflammatory effects of GLP-1 medicines independent of weight loss Several GLP-1 medicines, including semaglutide, liraglutide, and exenatide, reduce plasma levels of C-reactive protein (CRP), a surrogate of systemic inflammation, in people with obesity or T2D
Unlike semaglutide, which targets GLP-1 only, or tirzepatide (GLP-1 + GIP), Retatrutide adds glucagon receptor activity that increases resting energy expenditure, a mechanism not present in either predecessor
A 1-unit error at this concentration represents 0.2mg, a 20% dosing error
It also made the purification of insulin preparations much easier and was a key stepping stone to the biosynthetic production of human insulin (Philipson, Bell, Polonsky)